Group performance at a glance

Transcription

1 09 Roche in Brief Excellence in Science

2 Our Business Innovation is our answer to medical challenges. Our daily work is saving patients lives and helping millions of people around the world through excellence in science. Focus on unsolved medical problems For more than 110 years Roche has played a pioneering role in healthcare. Today, as the world leader in in vitro diagnostics, we supply a wide range of diagnostic instruments and tests for rapid and reliable disease detection and monitoring by doctors, laboratories and patients themselves. As the world s largest biotech company Roche has brought many highly effective drugs to market and become the world s leading supplier of prescription drugs for cancer treatment. Our daily work focuses on disease areas where medical needs are great. These include cancers, viral infections, metabolic and central nervous system disorders and inflammatory diseases. Roche is a pioneer in personalised healthcare: we aim to fit treatments as closely as possible to patients needs to make healthcare better, safer and more cost-effective.

3 Key figures 2009 Sales by division in millions of CHF Sales by geographical area in millions of CHF Pharma 38,996 (+11%) Diagnostics 10,055 (+9%) Europe 18,286 Africa and Asia Pacific 4,633 Japan 5,036 Latin America 2,940 North America 18,156 Italics = growth rates (in local currencies). Employees by operating division (full-time equivalents, FTE) Employees by region (full-time equivalents, FTE) Pharma 48,341 Other 567 North America 25,412 Africa 795 Latin America 4,930 Asia 14,169 Diagnostics 25,967 Chugai 6,632 Australia 891 Europe 35,310 Our Business Roche in Brief 1

4 Group performance at a glance Sales by division in millions of CHF Operating profit* in millions of CHF 9,189 11,730 14,468 13,896 15, Operating free cash flow in millions of CHF Net income in millions of CHF 6,828 8,560 10,671 12,378 15,722 6,866 9,171 11,437 10,844 8,510 27,268 8,243 33,294 8,747 36,783 9,350 35,961 9,656 38,996 10, Pharmaceuticals Diagnostics * Before exceptional items. 2 Roche in Brief Our Business

5 Core EPS in CHF Proposed by the Board of Directors. Dividend per share in CHF Price development of non-voting equity security (Genussschein) in CHF Pharmaceuticals In 2009 demand for key medicines and efficiency gains resulted in doubledigit increases in sales and operating profit. The division is focused on translating excellence in science into effective medicines for patients. It combines cutting-edge research at Roche, Genentech, Chugai and over 150 partners worldwide with global scale and reach in clinical development, manufacturing and commercial operations Roche non-voting equity security Swiss Market Index (rebased) For a full index of key facts and figures used in the report see: Our Business Roche in Brief 3

6 Pharmaceuticals pipeline Focused on compounds with first-in-class or best-in-class potential Phase III Project ID Project/Product Indication RG105 MabThera/Rituxan indolent NHL maint, 1st-line RG105 MabThera/Rituxan ANCA-associated vasculitis RG340 Xeloda+ adj colon cancer RG1569 Actemra/RoActemra JIA, systemic onset RG340 Xeloda adj breast cancer RG1569 Actemra/RoActemra early rheumatoid arthritis +MabThera diffuse large B cell lymphoma RG1594 ocrelizumab rheumatoid arthritis, PJD adj colon cancer RG3648 Xolair asthma, add-on therapy prostate cancer adj breast cancer HER2+ ovarian cancer, 1st-line +Herceptin mbc, HER2+, 1st-line adj NSCLC met gastric cancer adj breast cancer HER2 adj BC, triple negative mbc HER2, combo hormonal therapy ovarian cancer platinum-sensitive mbc, 2nd-line high-risk carcinoid GBM, 1st-line RG597 Herceptin SC formulation, BC HER2+ RG597 Herceptin adj BC HER2+, 2-yr treatment RG1273 pertuzumab mbc HER2+ RG1415 Tarceva NSCLC EGFR mutation-positive, 1st-line RG1415 Tarceva adj NSCLC RG1415 Tarceva+ NSCLC maint, 1st-line Blue type First indication RG7159 anti-cd20 humab chronic lymphocytic leukemia Black type Additional indications RG7204 BRAF inh malignant melanoma RG3502 trastuzumab-dm1 mbc HER2+, 2nd-line RG-No. Roche and/or Genentech managed Phase III Large-scale studies in patients for statistical confirmation of safety and efficacy Project/Product Indication Inflammation and autoimmune disorders Oncology Project ID Cardiovascular and metabolic diseases RG1583 taspoglutide type 2 diabetes RG1658 dalcetrapib dyslipidemia RG3645 Lucentis diabetic macular edema RG3645 Lucentis AMD, high dose RG3625 TNKase catheter clearance Ophthalmology Others Selected abbreviations Legend Therapeutic protein, other biologic Small molecule adj AMD BC combo GBM HER2+ HER2 hu inh JIA MAb maint m, met NHL NSCLC PJD SC adjuvant treatment age-related macular degeneration breast cancer combined with glioblastoma multiforme HER2-positive HER2-negative humanised inhibitor juvenile idiopathic arthritis monoclonal antibody maintenance treatment metastatic (cancer) non-hodgkin s lymphoma non-small cell lung cancer prevention of joint destruction subcutaneous Current as of January 2010

7 Sales in mchf Operating profit in mchf Number of employees 36,783 35,961 38,996 13,042 12,974 14,154 55,091 54,141 54, Key figures % change % change in In millions of CHF in CHF local currencies % of sales Sales 38, United States 14, Western Europe 10, Japan 4, International (Asia Pacific, CEMAI, 8, Latin America, Canada, Others) Operating profit before exceptional items 14, Operating free cash flow 14, Research and development 8, Sales by region United States 38% (+5%) Asia Pacific 5% (+20%) Latin America 6% (+7%) Other regions 3% (+12%) CEMAI 8% (+13%) Western Europe 28% (+12%) Japan 12% (+29%) Italics = growth rates (local currencies). CEMAI: Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent. Sales by therapeutic area Oncology 53% (+8%) Inflammatory and autoimmune diseases, transplantation 8% ( 6%) Central nervous system 2% ( 5%) Respiratory 3% (+8%) Metabolic diseases, bone diseases 7% ( 4%) Infectious diseases 1% ( 8%) Cardiovascular diseases 3% ( 2%) Virology 15% (+79%) Others 2% ( 29%) Renal anemia 3% (0%) Ophthalmology 3% (+24%) Pharmaceuticals Roche in Brief 7

8 Top-selling pharmaceuticals Roche Group Sales Product Active substance Indications in mchf % change* bevacizumab colorectal cancer, breast cancer, non-small 6, % cell lung cancer, kidney cancer, glioblastoma MabThera/Rituxan rituximab non-hodgkin s lymphoma, chronic 6,087 +6% lymphocytic leukemia, rheumatoid arthritis Herceptin trastuzumab HER2-positive breast cancer 5,266 +8% Tamiflu oseltamivir treatment and prevention 3, % of influenza A and B Pegasys peginterferon alfa-2a hepatitis B and C 1,655 +5% CellCept mycophenolate mofetil transplantation 1,576 22% NeoRecormon, epoetin beta anemia 1,560 11% Epogin Tarceva erlotinib advanced non-small cell lung cancer, 1, % advanced pancreatic cancer Xeloda capecitabine colorectal cancer, breast cancer, stomach cancer 1,260 +7% Lucentis** ranibizumab wet age-related macular degeneration 1, % * In local currencies. ** US sales. 8 Roche in Brief Pharmaceuticals

9 Major regulatory filings in Product Active substance Indication and/or dosage form Country bevacizumab relapsed glioblastoma multiforme Switzerland first-line metastatic breast cancer, combination, USA, Japan, with standard chemotherapy Switzerland ED-71 eldecalcitol osteoporosis Japan Epogin epoetin beta chemotherapy-induced anemia Japan Herceptin trastuzumab advanced HER2-positive gastric cancer, Switzerland Lucentis ranibizumab macular edema following retinal vein occlusion USA MabThera/ rituximab rheumatoid arthritis patients with an inadequate, Switzerland Rituxan response to a disease-modifying antirheumatic drug; prevention of joint damage first-line chronic lymphocytic leukemia USA relapsed or refractory chronic lymphocytic leukemia, USA, Switzerland RG744 methoxy polyethylene renal anemia Japan (Mircera) glycol-epoetin beta Tarceva erlotinib non-small cell lung cancer, first-line maintenance, USA, after chemotherapy Switzerland advanced pancreatic cancer Japan Xeloda capecitabine adjuvant colon cancer, combination with oxaliplatin, Switzerland 1 Includes supplemental indications; updated to 8 January Major regulatory approvals in Product Active substance Indication and/or dosage form Country bevacizumab relapsed glioblastoma multiforme USA 2, Switzerland metastatic breast cancer; combination with docetaxel first-line metastatic renal cell carcinoma, combination with interferon alfa-2a unresectable advanced or recurrent non-squamous non-small cell lung cancer, Switzerland USA Japan MabThera/ rituximab relapsed or refractory chronic, Switzerland Rituxan lymphocytic leukemia first-line chronic lymphocytic leukemia rheumatoid arthritis, guidance on retreatment in patients with an inadequate response to anti-tnf therapy Actemra/ tocilizumab rheumatoid arthritis signs and symptoms, USA RoActemra Xeloda capecitabine advanced or refractory colorectal cancer, Japan combination with oxaliplatin, with or without 1 Includes supplemental indications; updated to 8 January Accelerated approval (FDA). USA Pharmaceuticals Roche in Brief 9

10 Diagnostics Sales again significantly outpaced the market, helped by strong uptake of new products. All five business areas launched major products during the year. Efforts to enhance efficiency contributed to higher operating profit in The division will expand these efforts in order to improve profitability further.

11 Sales in mchf Operating profit in mchf Number of employees 9,350 9,656 10,055 1,648 23,062 25,404 25,967 1,187 1, Key figures % change % change in In millions of CHF in CHF local currencies % of sales Sales 10, Professional Diagnostics 4, Diabetes Care 2, Molecular Diagnostics 1, Applied Science Tissue Diagnostics Operating profit 1, Operating free cash flow 1, Research and development Sales by region Europe/Middle 53% (+9%) East/Africa Japan 5% (+0%) Asia Pacific 10% (+25%) Latin America 6% (+15%) North America 26% (+4%) Italics = growth rates (in local currencies). Top-selling diagnostics Sales Product line Market segment in mchf % change* Accu-Chek Diabetes management 2,969 +6% cobas e modules, Modular Analytics, Elecsys Immunoassays 1, % cobas c modules, Modular Analytics, Cobas Integra Clinical chemistry 1,275 +4% Cobas AmpliPrep, Cobas TaqMan Virology % Cobas AmpliScreen, cobas TaqScreen Blood screening % CoaguChek meters Coagulation monitoring % Immunohistochemistry reagents Advanced tissue staining % MagNa Pure Systems, Light Cycler Systems Gene expression research % Sysmex analysers Hematology % 454 Genome Sequencers DNA sequencing % * In local currencies. Diagnostics Roche in Brief 11

12 Major product launches in 2009 Product Professional Diagnostics cobas c701 and c502 modules: First clinical chemistry modules for the cobas 8000 analyser series for high-throughput laboratories cobas p 501 and cobas p 701: Automated post analytical sample storage and retrieval modules for bar-coded primary and secondary sample tubes Sysmex XT-4000i: Hematology analyser for mid- to high-volume testing Immunoassays for PlGF (placenta growth factor) and SFlt1 (soluble fms-like tyrosine kinase 1): Diagnosis of preeclampsia Immunoassay for anti-ccp (anti-cyclic citrullinated peptide antibody): Diagnosis of rheumatoid arthritis Immunoassay for IL-6 (interleukin-6): Aid in managing critically ill patients and monitoring course of disease High-sensitivity immunoassay for troponin T: Diagnosis of heart attack and cardiac risk stratification Immunoassay for troponin I: Prediction of mortality risk in patients with acute coronary syndrome, diagnosis of heart attack and cardiac risk stratification Diabetes Care Accu-Chek Aviva Nano and Accu-Chek Performa Nano: Sleeker versions of the Accu-Chek Aviva and Accu-Chek Performa meters offering an enhanced feature set Accu-Chek Active: New version of existing system, featuring extended memory and a number of fail-safe capabilities Accu-Chek Mobile: Integrated lancing and blood glucose monitoring device employing a unique no strip technology Accu-Chek Combo: Interactive diabetes management system combining an insulin pump and a blood glucose meter Molecular Diagnostics CT/NG test on cobas 4800 system: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae HPV test on cobas 4800 system: Detection of human papillomavirus LightCycler MRSA Advanced Test: Identification of carriers of methicillin-resistant Staphylococcus aureus TheraScreen EGFR 29 mutation test: Aids doctors in determining patients suitability for certain cancer therapies Applied Science LightCycler 1536 system: High-throughput quantitative PCR analysis MagNa Pure 96 system: High-throughput system for preparing nucleic acid samples NimbleGen MS 200 scanner: High-resolution microarray scanner for use with NimbleGen HD2 high-density microarrays xcelligence RTCA DP system: Medium-throughput system for real-time non-invasive cell analysis Tissue Diagnostics INFORM EGFR DNA Probe: Quantitatively detects EGFR gene expression using silver chromogenic in situ hybridisation (SISH) CONFIRM anti HER2/neu Primary Antibody: Qualitative detection of protein over-expression in breast and gastric tissue samples INFORM HER2 DNA Probe: Detects HER2 gene status in breast and gastric tissue samples BenchMark Ultra: Advanced staining system with continuous and random processing and STAT capabilities BenchMark XT: Fully automated instrument for advanced staining Symphony: Instrument for primary staining Vantage Information Solution: Workflow information management system for the anatomical pathology laboratory Market Contractual territories in EMEA US, US Worldwide Worldwide Worldwide Worldwide EMEA, APAC EMEA, APAC EMEA, APAC, LATAM, J LATAM, APAC = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia Pacific; LATAM = Latin America; US = United States; J = Japan. 12 Roche in Brief Diagnostics

13 Major product launches planned for Product Professional Diagnostics cobas e 602 module: Immunoassay module for the cobas 8000 modular analyser series, US for high-volume laboratories cobas c 701 and cobas c 502 modules: Clinical chemistry modules for the cobas 8000 modular US analyser series cobas c 702 module: Advanced clinical chemistry module for the cobas 8000 modular analyser series cobas p 501 and cobas p 701: Automated post analytical sample storage and retrieval modules US for bar-coded primary and secondary sample tubes cobas b 123: Benchtop multiparameter analyser for use in critical care settings at the point of care Eight Elecsys immunoassays in the US; six in the, US Diabetes Care Accu-Chek Aviva Nano: Sleeker version of the Accu-Chek Aviva meter offering US an enhanced feature set Accu-Chek Mobile: Integrated lancing and blood glucose monitoring device Additional employing a unique no strip technology markets, APAC Accu-Chek Combo: Interactive insulin delivery system combining an insulin pump Additional and a blood glucose meter markets, APAC, US Molecular Diagnostics LightCycler MRSA Advanced Test: Identification of carriers of methicillin-resistant US Staphylococcus aureus Cobas AmpliPrep/Cobas TaqMan CMV: Viral load monitoring test to improve the management of cytomegalovirus disease cobas TaqScreen DPX Test: Blood Screening test designed to simultaneously provide a quantitative result for parvovirus B19 and a qualitative result for hepatitis A virus Cobas AmpliPrep/Cobas TaqMan HIV-1 v2: Second-generation test enabling detection US of two separate regions of the HIV-1 genome Cobas TaqMan 48 HIV v2: Manual sample preparation option for customers with a low-volume workload Applied Science GS Junior System: Next-generation DNA sequencing system for smaller laboratories Worldwide NimbleGen CGX-6 multiplex arrays: Microarrays for high-resolution analysis Worldwide of chromosomal abnormalities xcelligence RTCA HT instrument: Automated high-throughput real-time cell analyses Worldwide and screening SeqCap EZ Exome v.2: In-solution enrichment capture technology for targeted Worldwide next-generation sequencing Next-generation ultra-high density NimbleGen microarrays Worldwide Tissue Diagnostics Dual colour/dual hapten in situ hybridisation (ISH) kit: For use with all molecular markers, specifically to support HER2 testing Anti-HER2 neu primary antibody and HER2 DNA probe: For assessing likelihood of response to Herceptin treatment in both breast and gastric cancer patients BenchMark GX: Low-volume advanced tissue staining platform that automates, APAC all slide processing steps from baking to staining Molecular probes targeting the enzyme TOP2A and cell surface receptor IGF1R: For use as an aid in diagnosing and managing breast and lung cancer Discovery Ultra platform: For immunohistochemistry (IHC) and in situ hybridisation (ISH) US,, APAC, research, offering significant improvements in ease of use, workflow and flexibility Japan, LATAM 1 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia Pacific; LATAM = Latin America; US = United States. Market Diagnostics Roche in Brief 13

14 Corporate Responsibility Our goal is to develop products and services that address unmet medical needs, improve patients health and quality of life and are of real value to society. We conduct our business in a responsible, sustainable manner that respects the needs of the individual, society and the environment.

15 Sustainability In brief In our Corporate Principles we make the commitment to maintain high ethical and social standards in our business dealings, in our approach to medical science, in our efforts to protect the environment and to ensure good citizenship. We maintain these standards by adhering to local, national and international laws and regulations, by cooperating with authorities and by proactive dialogue with stake-holders. Patients Within our businesses pharmaceuticals and diagnostics we prioritise in areas of significant unmet need where we have the expertise to make a difference. Our aim is to develop new and improved medicines and diagnostic tests offering significant benefits over existing options, with a focus on personalised healthcare. This means patients can lead longer and better lives because they receive treatments that more effectively prevent and cure disease, alleviate symptoms and hasten recovery. Society Our support for communities focuses on programmes and areas that are aligned with our business model. We believe we can enhance the innovation, sustainability and impact of our business through appropriate donations, sponsorship and employee volunteering. This inspires and motivates our staff and ensures Roche remains a committed corporate citizen. People Our history of achieving our business goals and excelling in science and innovation is a result of consistently employing the best people people who are passionate about making a difference to patients lives; people who lead and drive change; people who live our corporate values integrity, courage and passion. We keep our employees engaged and performing at the highest level by creating a working environment in which everyone feels valued and respected; where they can develop to their fullest potential and can make their own mark. Our progress in achieving this is illustrated by our consistent ranking as an Employer of Choice. Safety, security, health and environmental protection Protection of the environment and conservation of resources is a key concern at Roche. We take safety, security, health and environmental matters (SHE) into consideration in all our activities, and they are handled with the same sense of responsibility, and just as methodically, as issues concerning quality, productivity and costefficiency. Careful use of resources with minimal environmental impact is an important element in sustainable development. Corporate Responsibility Roche in Brief 15

16 Key performance indicators of the Roche Group Economic and business performance in millions of CHF Sales (mchf) 49,051 45,617 46,133 Research and development (mchf) 9,874 8,845 8,385 Research and development as % of sales 20.1% 19.4% 18.2% Operating profit before exceptional items (mchf) 15,012 13,896 14,468 Operating profit margin 30.6% 30.5% 31.4% Net financial income (mchf) 1, Net Income (mchf) 8,510 10,844 11,437 Core earnings per share (CHF) Operating free cash flow 15,722 12,378 10,671 Operating free cash flow as % of sales 32.1% 27.1% 23.1% Net assets (mchf) 9,414 53,822 53,443 Net cash (debt) (mchf) 23,867 16,682 17,336 Equity ratio 12.63% 70.70% 68.2% Increasing value for our shareholders and investors Dividend per share (CHF) 1) Dividend (mchf) 1) 5,175 4,313 3,968 Dividend as % of sales 10.6% 9.5% 8.6% Payout Ratio 53% 49% 41% Price of non-voting equity security (Genussschein) at 31 st of December (CHF) Market capitalization (CHF billions) Total Shareholder Return (TSR) at 31 st of December 12% 16.0% 9.8% Dow Jones World and FTSE4Good sustainability indexes Leader Included Included Access to healthcare & patients benefits Number of major regulatory approvals received Number of major regulatory filings Patients actively participating in clinical trials 2) 269, , ,752 Patients benefiting from Patient Assistance Programs (US only) 40,000 38,000 34,480 Number of phase I III clinical trials at 31 st of December Number of clinical trial protocols (Phase I IV) published % of all HIV/AIDS patients living in countries eligible for no-profit Roche ARV medicines 68% 68% 70% % of all HIV/AIDS patients living in countries eligible for reduced-price Roche ARV medicines 83% 83% 86% Technology Transfer Initiative (TTI) agreements with companies covering sub-saharan Africa and the least developed countries (LDCs) Roche in Brief Corporate Responsibility

17 Commitment to our employees Number of employees (full-time equivalent FTE) 81,507 80,080 78,604 Growth in full-time equivalent employees 1,427 1,476 4,232 Total employees remuneration (mchf) 12,080 11,129 10,767 Total employees remuneration as % of sales 24.6% 24.4% 23.3% Percentage of women in total workforce 46% 46% 45% Percentage of women in management positions 37% 37% 32% Staff turnover (fluctuation) 7% 9.9% 8.7% Average number of training hours per employee Numbers of Employees on Roche secondment Percentage of eligible employees purchased shares through Roche CONNECT 37% 36% 36% Roche s position in Science magazine s top employers in the biotech and pharmaceutical industries 17 th 6 th 18 th Genentech s position in Science magazine s top employers in the biotech and pharmaceutical industries 1 st 1 st 2 nd Commitment to society and the communities we operate in Income taxes (mchf) 2,870 3,305 3,867 Income taxes as % of sales 5.9% 7.2% 8.4% Community support by area: Humanitarian and social projects 75% 86% 85.5% Science and education 17% 11% 11.2% Arts and culture 5% 2% 1.8% Community and environment 3% 1% 1.5% Safety, health and environmental protection Investments in SHE (mchf) Operating costs for SHE (mchf) Roche Accident Rate Occupational accidents Occupational accidents per million working hours Occupational illnesses Eco-Efficiency Rate eco-balance Total energy consumption (TJ/year) 13,898 13,662 13,664 Total energy consumption (TJ/year per mchf sales) Greenhouse gas emissions (tonnes CO 2 equivalents) 1,053,118 1,062,114 1,052,407 Greenhouse gas emissions (tonnes CO 2 equivalents per mchf sales) NO x (t/year) SO 2 (t/year) Volatile organic compounds (VOCs) (t/year) Particulate matter (t/year) Water consumption (million cubic meters per year) Water consumption (cubic meters per year per mchf sales) Total organic carbon (TOC) (t/year) Heavy metals (kg/year) Chemical waste (t/year) 27,605 31,295 38,167 General waste (t/year) 19,828 42,823 17,480 1) For the year 2009 as proposed by the Board of Directors. 2) Clinical development phases I to IV. Figures for 2007 as in Annual Report Corporate Responsibility Roche in Brief 17

18 Progress and achievements in 2009 Responsible practices Patients and access to healthcare People Society Safety, health and environmental protection Named Healthcare Super Sector Leader in Dow Jones Sustainability Indexes. Reselected for the DJSI World and STOXX indices and the FTSE4Good index. Produced five new position papers on: stem cells and cloning; nanotechnology; biobanks; personalised healthcare; and the value of our products and services. Launched Group-wide phone line and web-based system for reporting violations of our Code of Conduct. Developed new Supplier Code of Conduct to describe our requirements in ethics; safety, health an environment; innovation; supplier diversity; economic sustainability and social responsibility. OneWorld Health completed first screening of Roche s chemical compound library to find new drugs to treat diarrhea. Joined a public-private partnership with Novo Nordisk and the World Diabetes Foundation to improve care for children with diabetes in Africa. Donated 5.65 million additional Tamiflu courses to replenish WHO stockpiles. Launched Tamiflu Reserves Program to increase access in developing countries. Provided free treatment to 40,500 patients in the US through the Roche/Genentech Access programmes. Disclosed all financial and in-kind support for patient organisations on our website. Global employee Listening to You survey resulted in 91% of employees expressing job satisfaction at Roche. Genentech voted Science magazine s top employer for the seventh time. Rolled out globally aligned performance management and compensation principles and began to align these between Genentech and Roche. Expanded global leadership programme portfolio, providing key programmes at every stage in the leadership development and talent pipeline. Launched new Corporate policy on philanthropic donations and non-commercial sponsorship. Launched cancer awareness campaign in rural South Africa, which trains nursing staff, offers free screening for breast, cervical and prostate cancers, and raises awareness of the disease. Produced manual on energy efficient design standards for our buildings. Launched e-learning programme on safety, security, health and environmental protection for all employees. Launched the Roche Environmental Awareness in Chemical Technology (REACT) programme to reduce the environmental impact of our products. No. of Security securities Listing Trading Symbol CUSIP/ISIN Voting share 160,000,000 SIX Swiss Exchange SIX Swiss Exchange RO CH Non-voting equity 702,562,700 SIX Swiss Exchange virt-x ROG CH security (NES) ADR Note a) OTCQX OTCQX RHHBY Note a) The number of ADRs in issue varies depending on demand and conversion in and out of the underlying non-voting equity security (NES). 18 Roche in Brief Our Business

19 Published by F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Tel (0) Fax + 41 (0) Media Office Group Communications 4070 Basel, Switzerland Tel (0) Fax + 41 (0) Investor Relations 4070 Basel, Switzerland Tel (0) Fax + 41 (0) World Wide Web Corporate Sustainability Committee Tel (0) [email protected] To order publications Tel (0) Fax + 41 (0) [email protected] Cautionary statement regarding forward-looking statements Roche in Brief contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in Roche in Brief, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for 2009 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche in Brief is published in English and is issued by F. Hoffmann-La Roche Ltd, Basel, Group Communications. Printed on non-chlorine bleached, FSC-certified paper.

20 F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland 2010 All trademarks are legally protected